(Reuters) - The agency has "considerable concern" about data that show
a signal of possible heart attack risks with Avandia, a summary
from FDA staff said. Various data present "somewhat
inconsistent findings" on the risk, it added.
The agency released the analysis ahead of Monday's advisory
panel review of the drug's heart risks.
Read more at Reuters.com Government Filings News
a signal of possible heart attack risks with Avandia, a summary
from FDA staff said. Various data present "somewhat
inconsistent findings" on the risk, it added.
The agency released the analysis ahead of Monday's advisory
panel review of the drug's heart risks.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment